Effects and mechanisms of the functional parts of Dahuang Zhechong Pill containing serum on platelet-derived growth factor-stimulated proliferation of vascular smooth muscle cells

Chinese Journal of Integrative Medicine

Volumn 19, Issue 6, 2013, Pages 432-438

  Liu, Na ^a   Liu, Jun Tian ^a   Ji, Yuan Yuan ^a   Lu, Pei Pei ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

cell cycle; cyclin D1; Dahuang Zhechong Pill; p27; proliferation

Indexed keywords

CHINESE DRUG; CYCLIN D1; DAHUANG ZHECHONG PILL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C ALPHA; PROTEIN P27; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CIRCULATION; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; FLOW CYTOMETRY; HEMOSTASIS; IMMUNOCYTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; CELL CYCLE; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA; DRUGS, CHINESE HERBAL; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MALE; MAP KINASE SIGNALING SYSTEM; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE C-ALPHA; RATS; RATS, SPRAGUE-DAWLEY; SERUM;

EID: 84879635070     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-012-1033-y     Document Type: Article

References (28)

1. Libby P. Inflammat ion in atherosclerosis. Nature 2002;420:868-874.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
3. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995;57:791-804.
4. Sachinidis A, Locher R, Vetter W, Tatje D, Hoppe J. Different effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells. J Biol Chem 1990;265:10238-10243.
5. Yan JJ, Chen XY. The progress of experiment study on Dahuang Zhechong Pill. Chin J Exp Tradit Med Formul (Chin) 2000;6:60-61.
6. Chen JF. Efficacy of Dahuang Zhechong Pill in treatment of 50 cases of patients with carotid atherosclerosis. Shandong J Tradit Chin Med (Chin) 2001;20:331-332.
7. Li WL, Wu SP. Clinical effect of Dahuang Zhechong Pill on chronic hepatitis with hepatic fibrosis. China Pharm (Chin) 2008;19:1658-1659.
8. Yuan HX. Clinical application of Dahuang Zhechong Pill in gynecology. J Chin Integr Med (Chin) 2009;7:168-170.
9. Li JL, Liu JT, Gou W, Li XK, Liu CH. Effect of Dahuang Zhechong Pill on vascular smooth muscle cells in atherosclerotic rabbits. Chin Tradit Patent Med (Chin) 2006;28:1470-1472.
10. Zhang YH, Liu JT, Wen BY, Xiao XH. In vitro inhibition of proliferation of vascular smooth muscle cells by serum of rats treated with Dahuang Zhechong Pill. J Ethnopharmacol 2007;112:375-379.
11. Zhang YH, Liu JT, Wen BY, Liu N. Mechanisms of inhibiting proliferation of vascular smooth muscle cells by serum of rats treated with Dahuang Zhechong Pill. J Ethnopharmacol 2009;124:125-129.
12. Tashino S. "Serum pharmacology" and "serum pharmaceutical chemistry": from pharmacology of Chinese traditional medicines to start a new measurement of drug concentration in blood. Ther Drug Monit Res 1988;5:54-64.
13. Skalli O. A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 1986;103:2787-2796.
14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytoxicity assays. J Immunol Methods 1983;95:55-63.
15. Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 1982;218:474-475.
16. Darzynkiewicz Z, Bedner E, Smolewski P. Flow cytometry in analysis of cell cycle and apoptosis. Semin Hematol 2001;38:179-193.
17. Blake MS, Johnston KH, Russell-Jones GJ, Gotschlich EC. A rapid, sensitive method for detection of alkaline phosphatase-conjugated anti-antibody on Western blots. Anal Biochem 1984;136:175-179.
18. Meng YC, Ding X, Ben CE. The application view of Chinese traditional medicine serum pharmacology. J Beijing Univ Tradit Chin Med (Chin) 1999;22:42-43.
19. Lavoie JN, Allemain GL, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/ p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996;71:20608-20616.
20. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994;79:551-555.
21. Morgan DO. Principles of CDK regulation. Nature 1995;374:131-134.
22. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1 phase progression. Gene Dev 1999;13:1501-1512.
23. Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res 1998;82:396-403.
24. Graf K, Xi XP, Yang D, Fleck E, Hsueh WA, Law RE. Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 1997;29:334-339.
25. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, et al. ERKs: a family of proteinserine/ threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991;65:663-675.
26. Wilkinson MG, Millar JBA. Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J 2000;14:2147-2157.
27. Saito Y, Hojo Y, Tanimoto T, Abe J, Berk BC. Protein kinase C-α and protein kinase C-É are required for Grb2-associated binder-1 tyrosine phosphorylation in response to plateletderived growth factor. J Biol Chem 2002;277:23216-23222.
28. Okazaki J, Mawatari K, Liu B, Kent KC. The effect of protein kinase C and its alpha subtype on human vascular smooth muscle cell proliferation, migration and fibronectin production. Surgery 2000;128:192-197.